The court order provided a schedule of actions designed to resolve antitrust issues related to the deal.
The companies appear poised to return to court to settle Alere's claim that Abbott needs to quickly fulfill its obligations under their merger deal.
The Alere flu test detected fewer cases of influenza A in a recent study, which researchers attributed to low viral loads.
The firm's confirmation that it is on track with current and Q3 financial report timing may not be enough to appease would-be acquirer Abbott.
Alere filed a legal complaint in order to push Abbott to obtain the anti-trust approvals needed to complete the acquisition proposed earlier this year.
Although the financial filing sheds increased light on Alere's business, the company is asking for an extension to file its second quarter financial statements.
While Abbott continues to express concerns about the pending acquisition, Alere has remained resolute in its response.
The firm also reported that it has corrected immaterial errors in previous financial statements.
Abbott's MDx sales were driven by continued strong growth in its infectious disease testing business but were partly offset by the planned scale down of its genetics business.
The release clarifies issues related to the timing of revenue recognition for transactions outside the US.